Articles

RSS

ALACHUA, FL - Florida Biologix®, a full-service biopharmaceutical development and contract manufacturing organization, announced that it has entered into a cGMP manufacturing agreement with the National Taiwan University Hospital. Under the agreement, Florida Biologix will produce a Phase I clinical batch of their novel therapy for a rare genetic disease – AADC deficiency.

"We are excited to support another major clinical project just into our second year of operation," said Dr. Richard Snyder, Director of Florida Biologix. "Our specialized experience in the manufacture, testing and filling of biopharmaceuticals combined with our unique business model makes us an ideal partner to work with the National Taiwan University Hospital. As with all of our client companies, we will work closely with their team to help them achieve their manufacturing objectives."

"We are very excited to have Florida Biologix produce our investigational therapy for patients in Taiwan" said Dr. Paul Wuh-Liang Hwu. "They have a track record of expertise in biopharmaceutical manufacturing and testing, including capabilities to make material for both pre-clinical and clinical trials."

For more information on Florida Biologix, visit their website at www.floridabiologix.ufl.com